Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Prevention of relapse in pediatric patients with acute leukemias and MDS after allogeneic SCT by early immunotherapy initiated on the basis of increasing mixed chimerism: a single center experience of 12 children

Abstract

The success of allogeneic stem cell transplantation (allo-SCT) in children is mainly affected by relapse or graft rejection. We have recently shown in a study of 55 patients with acute leukemias (ALL 21, AML 20 and MDS 14), that patients who demonstrate increase amounts of autologous marrow repopulation (increasing mixed chimerism) have a significantly enhanced risk of relapse (P < 0.0001). based on these findings, we asked whether post-transplant relapse can be prevented by withdrawal of immunosuppression and/or by donor lymphocyte infusion (dli). we describe the results of a pilot study where adoptive immunotherapy was used to treat 12 patients (five all, three aml, four mds) who showed increasing mixed chimerism (mc) post-transplant. a response to immunotherapy, defined as the re-establishment of complete chimerism (cc) and continuous complete remission (ccr), was achieved in four patients (two all, two aml) following withdrawal of csa and in a further six patients (three all, three mds) after additional dli. one all patient, who initially responded to dli, developed severe gvhd that required further immunosuppression. gvhd was controlled but this patient subsequently relapsed. another patient with all became a cc but developed an isolated relapse in the bone marrow 260 days later. one patient with mds developed severe gvhd after dli and died. two children (one aml and one mds) did not show any response to interventional treatment and died due to relapse. of the 12 patients treated, seven remain in ccr at a median follow-up of 747 days (range 351–1109 days). in summary, these results provide evidence that increasing mc can be used to guide adoptive immunotherapy strategies and that these treatment modalities can be used to prevent relapse in children with acute leukemias or mds after allo-sct.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bader, P., Klingebiel, T., Schaudt, A. et al. Prevention of relapse in pediatric patients with acute leukemias and MDS after allogeneic SCT by early immunotherapy initiated on the basis of increasing mixed chimerism: a single center experience of 12 children. Leukemia 13, 2079–2086 (1999). https://doi.org/10.1038/sj.leu.2401581

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2401581

Keywords

This article is cited by

Search

Quick links